Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 73.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 104,560 shares of the company's stock after selling 286,146 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.18% of Black Diamond Therapeutics worth $224,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in BDTX. Bank of New York Mellon Corp lifted its position in Black Diamond Therapeutics by 46.1% during the fourth quarter. Bank of New York Mellon Corp now owns 207,074 shares of the company's stock worth $443,000 after buying an additional 65,341 shares during the period. Wellington Management Group LLP increased its stake in shares of Black Diamond Therapeutics by 7.9% during the 4th quarter. Wellington Management Group LLP now owns 221,236 shares of the company's stock valued at $473,000 after acquiring an additional 16,279 shares during the last quarter. Barclays PLC lifted its holdings in shares of Black Diamond Therapeutics by 10.7% during the 4th quarter. Barclays PLC now owns 86,545 shares of the company's stock worth $186,000 after acquiring an additional 8,394 shares during the period. Sei Investments Co. acquired a new stake in shares of Black Diamond Therapeutics in the fourth quarter worth approximately $49,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Black Diamond Therapeutics in the fourth quarter worth approximately $53,000. Hedge funds and other institutional investors own 95.47% of the company's stock.

Wall Street Analysts Forecast Growth

BDTX has been the subject of several research analyst reports. HC Wainwright upped their price target on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a "buy" rating in a research report on Tuesday, March 18th. Stifel Nicolaus dropped their price objective on Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating for the company in a report on Friday, March 7th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a research report on Wednesday, March 19th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $14.60.

Insider Buying and Selling

In related news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the firm's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the sale, the insider now directly owns 2,733,547 shares in the company, valued at approximately $5,658,442.29. This trade represents a 67.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 8.87% of the stock is owned by corporate insiders.

Black Diamond Therapeutics Stock Performance

BDTX traded up $0.02 on Friday, reaching $1.95. 850,295 shares of the company's stock were exchanged, compared to its average volume of 1,498,059. Black Diamond Therapeutics, Inc. has a twelve month low of $1.20 and a twelve month high of $6.75. The company's 50 day moving average is $1.60 and its 200-day moving average is $2.12. The company has a market cap of $110.52 million, a price-to-earnings ratio of -1.47 and a beta of 2.63.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.03. Sell-side analysts forecast that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current year.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.